- Nasus Pharma Ltd. announced an **expanded agreement** with Aptar France S.A.S. and AptarGroup, Inc. on **October 8, 2025**, to support the development and commercialization of its **NS002 intranasal epinephrine program**.  **[2029039_0001493152-25-017378_ex99-1.htm:0]** **[2029039_0001493152-25-017378_ex99-1.htm:1]** 
- This collaboration provides Nasus Pharma with a **commercially proven Unit Dose System technology**, access to Aptar's technical expertise, manufacturing capabilities, and supply chain, aiming to **accelerate NS002's path to market** and **reduce development risks**.  **[2029039_0001493152-25-017378_ex99-1.htm:0]** 
- Under the new agreements, Aptar France will provide development, testing, and regulatory support for NS002, and will **exclusively supply** the Unit Dose Powder nasal delivery system (UDSp) devices to Nasus Pharma for its Epinephrine products, subject to FDA approval.  **[2029039_0001493152-25-017378_form6-k.htm:1]** 
- Nasus Pharma will compensate Aptar France with **staged fees** over three years, **milestone payments** upon new drug application (NDA) submission and approval, and **royalties** from commercial sales for seven years.  **[2029039_0001493152-25-017378_form6-k.htm:1]**

Nasus Pharma (NSRX)